PT - JOURNAL ARTICLE AU - Moss, Esther L. AU - Gorsia, Diviya N. AU - Collins, Anna AU - Sandhu, Pavandeep AU - Foreman, Nalini AU - Gore, Anu AU - Wood, Joey AU - Kent, Christopher AU - Stannard, Elizabeth A. AU - Silcock, Lee AU - Guttery, David S. TI - Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression AID - 10.1101/2020.03.04.20030908 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.04.20030908 4099 - http://medrxiv.org/content/early/2020/03/06/2020.03.04.20030908.short 4100 - http://medrxiv.org/content/early/2020/03/06/2020.03.04.20030908.full AB - Despite the increasing incidence of endometrial cancer (EC) worldwide and the poor overall survival of patients who recur, no reliable biomarker exists for detecting and monitoring EC recurrence and progression during routine follow-up. Circulating tumor DNA (ctDNA), the tumor-derived fraction of cell-free DNA (cfDNA) holds promise as a sensitive method for monitoring cancer activity and stratifying patients that are likely to respond to chemotherapy. Here, we investigated the utility of ctDNA for detecting and monitoring EC recurrence and progression in 13 patients using a combination of highly-sensitive digital droplet PCR (ddPCR), targeted next-generation sequencing (tNGS) and personalized ctDNA assays. Using the Oncomine™ Pan-cancer cfDNA tNGS panel, at least 1 somatic mutation at a variant allele frequency (VAF) >20% was detected in 69% (9/13) of patient tumors. The four patients with no detectable tumor mutations at >20% VAF were whole exome sequenced, with all four harbouring mutations in genes not analyzed by the Oncomine™ Pan-cancer cfDNA panel. Analysis of matched and longitudinal plasma DNA revealed earlier detection of EC recurrence and progression compared to standard clinical imaging techniques and dynamic kinetics of ctDNA levels reflecting treatment response. We also detected, for the first time to our knowledge, acquired high microsatellite instability (MSI-H) in ctDNA from one patient whose primary tumor was MSI stable. Overall, our study suggests that ctDNA analysis, and in particular MSI analysis in ctDNA could become a useful biomarker for early detection and monitoring of EC recurrence and progression.Competing Interest StatementLee Silcock is employed by Nonacus LimitedFunding StatementThis work was supported by a Hope Against Cancer/Leicester Precision Medicine Institute PhD studentship (DSG, DNG) in conjunction with the UK Department of Health on an Experimental Cancer Medicine Centre grant [C10604/A25151], and Medical Research Council (MRC) Proximity to Discovery scheme award [MCPC17194]. This research used the ALICE and SPECTRE High Performance Computing Facilities at the University of Leicester.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll WES data will be deposited in the European Genome-Phenome Archive on publication.